ArticleBlood cancer journal2021

A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.

Karthik Ramasamy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.